Objectives 1. Identify barriers to research engagement for patients who have undergone colectomy and pouch surgery for UC. 2. Develop and prioritize a patient-centered CER agenda to prevent and/or treat pouchitis and CLDP, unique, unfortunate, and rare diseases. 3. Identify, train, and empower a cohort of patients with or at-risk for pouchitis and CLDP to effectively partner in designing and conducting high-priority patient-centered CER.

The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease.

Phase 2b Induction: To evaluate the efficacy of icotrokinra versus placebo in inducing clinical response Phase 3 Induction: To evaluate the efficacy of icotrokinra versus placebo in induction Phase 3 Maintenance: To evaluate the efficacy of icotrokinra versus placebo in maintenance

We are studying how to make medical test results easier for patients to understand. Pathology reports, which explain what doctors find in tissue samples, are often written for medical professionals and can be hard for patients to read. In this study, we are testing whether artificial intelligence (AI) can help explain these reports in plain language. Patients having a routine screening procedure will read a sample report with or without an AI-generated explanation. Then they will answer questions about how well they understood the report and how they felt about it. We want to learn if using AI helps people better understand their health information and feel more confident making decisions. This will help improve the way test results are shared in the future.

1. Create a prospective cohort of well-phenotyped adult CD, UC and IBDU patients with serial clinical and patient-reported data collected throughout 12 months of Zymfentra (IFX -dyyb) therapy. 2. To determine clinical response and remission rates, course of stool calprotectin values and persistence of therapy with Zymfentra (IFX -dyyb) for induction and maintenance therapy. 3. Assess the correlation of various outcome measures in CD, UC or IBDU (short Crohn's disease activity index (sCDAI), Simple Clinical Colitis Activity Index (SCCAI), Urgency score, Fatigue,SIBDQ, PROMIS measures for depression, anxiety, and social satisfaction and work productivity and activity impairment. 4. Assess the effect of Zymfentra (IFX-dyyb) on patient reported fistula symptoms in patients with CD with pre-existing perianal fistulizing disease. 5. Assess persistence and need for dose escalation therapy of Zymfentra (IFX-dyyb). 6. Assessment of trough levels taken in the setting of standard of care before and after start of Zymfentra (IFX-dyyb).

The purpose of this project is to advance understanding of the relationship of food and eating characteristics with gastrointestinal symptoms on a population level, by examining the frequency, associated factors, and quality of life and emotional effects of eating-associated gastrointestinal symptoms.

To create a biorepository for future research studies to better improve patient treatment in care for patients with liver cancer and liver diseases

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is doing this study because they want to learn more about eosinophilic gastrointestinal disorders (EGIDs).

Assess the clinical response to treatment with mirikizumab among patients with chronic inflammatory conditions of the pouch using standardized outcome assessments.

For adults undergoing a standard of care biopsy for screening or surveillance of Barrett's Esophagus (BE). We are comparing two biopsy methods: Seattle biopsy versus WATS biopsy for the detection of intestinal metaplasia (change in the lining of your esophagus or 'food tube' to that of your stomach).